Alerje earns $1M Phase II SBIR grant

DETROIT–Alerje Inc., developers of new products for emergency medicine and food allergy management announced a Phase II grant award from the Small Business Innovation Research program of the National Science Foundation.

The $1 million grant will expand the capabilities of its patent-pending AI digital platform & will help accelerate the manufacturing of Alerje’s internationally patented epinephrine auto-injector system.

Alerje’s digital platform features a variety of food allergy remote therapeutic management tools, all designed to streamline the delivery of OIT regimens and ensure their successful completion by patients and doctors. The platform, which consistently achieved a user satisfaction rate of 92% during their Phase I NSF project, will continue to evolve in Phase II with the aim of enhancing user experience and ML capabilities.

Upon receiving the award, Javier Evelyn, Alerje’s founder and CEO, said: “We are deeply honored by the NSF’s continued support for our vision. Our patented device and digital platforms are poised to make life a bit easier and seamless as it relates to the treatment of food allergies, which affect over 220 million patients worldwide. This Phase II grant takes us one step closer to realizing that vision.” Evelyn is principal investigator on the grant.

The NSF SBIR program, marketed as “America’s Seed Fund,” awards more than $200 million annually to startups and small businesses, transforming scientific discovery into products and services with commercial and societal impact. Startups working across almost all areas of science and technology can receive up to $2 million to support research and development, helping de-risk technology for commercial success. America’s Seed Fund is congressionally mandated through the Small Business Innovation Research program. The NSF is an independent federal agency with a budget of about $9.5 billion that supports fundamental research and education across all fields of science and engineering. More at

Alerje builds emergency medicine and digital health products and services for the 220 million families worldwide impacted by food allergies. Included are systems to collect, store, analyze and distribute clinically relevant information for families, allergists, insurers, and the pharmaceutical industry, and a novel epinephrine auto-injector that integrates into a smartphone case for improved patient adherence improvement and alerts. More at

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.